Futile Radiotherapy for Patients With Cancer Near the End of Life - Scorecard - MDSpire

Futile Radiotherapy for Patients With Cancer Near the End of Life

  • By

  • Alok Deshane

  • Morgan Freret

  • Victoria S. Brennan

  • Puneeth Iyengar

  • Daniel R. Gomez

  • Divya Yerramilli

  • Amy J. Xu

  • June 15, 2026

  • 0 min

Share

Clinical Scorecard: Ineffectiveness of Radiotherapy in Terminal Cancer Patients Approaching End of Life

At a Glance

CategoryDetail
Condition
Key MechanismsPalliative radiotherapy may alleviate symptoms but is often inappropriate for end-of-life patients due to limited life expectancy and potential harms. Clarify the role of palliative care.
Target Population
Care Setting

Key Highlights

  • additional_highlight

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • A
      • d
      • d
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • m
      • e
      • t
      • r
      • i
      • c
      • s
      • f
      • o
      • r
      • a
      • s
      • s
      • e
      • s
      • s
      • i
      • n
      • g
      • t
      • r
      • e
      • a
      • t
      • m
      • e
      • n
      • t
      • e
      • f
      • f
      • i
      • c
      • a
      • c
      • y
      • a
      • n
      • d
      • p
      • a
      • t
      • i
      • e
      • n
      • t
      • o
      • u
      • t
      • c
      • o
      • m
      • e
      • s
      • .

      Risks

        Patient & Prescribing Data

        Discuss implications of high deferral rates for patient care.

        Clinical Best Practices

        • add_rationale

        Related Resources & Content

        Original Source(s)

        Futile Radiotherapy for Patients With Cancer Near the End of Life

        • by Alok Deshane, Morgan Freret, Victoria S. Brennan, Puneeth Iyengar, Daniel R. Gomez, Divya Yerramilli, Amy J. Xu

        • June 15, 2026

        Related Content

        Autophagy modulation in gynaecologic oncology: insights into immune regulation and therapeutic potential

        Who Decides How AI Enters Pathology?

        Liron Pantanowitz explains why validation, leadership, and real-world use matter more than performance metrics

        Correction: miR-17: from developmental regulatory hub to molecular engine driving tumourigenesis